Filing Flows › Dare Bioscience (DARE) › Q1 2026
Dare Bioscience (DARE) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
Dare Bioscience (DARE) reported revenue of $152K for the first quarter 2026 (Q1 2026), +500% from a year earlier and -85% from the quarter before.
Dare Bioscience, Q1 2026: revenue $152K (+500% year over year), net loss $3.0M, operating cash flow −$5.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $152K | -85% | +500% |
| Operating profit | −$3.0M | — | — |
| Net earnings | −$3.0M | — | — |
| Operating cash flow | −$5.5M | -482% | — |
What changed
Revenue was $152K in Q1 2026, up 500% year over year and down 85% from the previous quarter.
Operating costs exceeded revenue by $3.0M, an operating margin of -1967.1%. Total costs fell 32% while revenue rose 500%. The quarter ended with a net loss of $3.0M, wider than the previous quarter's $1.4M loss.
Operating cash flow was −$5.5M. Non-cash charges added back $555K of depreciation and amortization and $455K of share-based compensation. Working capital and other items used $3.5M.
Questions
What was Dare Bioscience's revenue in the first quarter 2026?
Dare Bioscience (DARE) reported revenue of $152K for the first quarter 2026 (Q1 2026), +500% from a year earlier and -85% from the quarter before.
Source: Dare Bioscience 10-Q on SEC EDGAR.